Want to see CCCC full AI Analyst Report?
Total Valuation
C4 Therapeutics has a market cap or net worth of $407.99M. The enterprise value is $154.35.
Market Cap$407.99M
Enterprise Value$154.35
Share Statistics
C4 Therapeutics has 110,567,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,567,220
Owned by Insiders2.97%
Owned by Institutions4.11%
Financial Efficiency
C4 Therapeutics’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -31.43%.
Return on Equity (ROE)-0.41
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-31.43%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee345.64K
Profits Per Employee-1.01M
Employee Count104
Asset Turnover0.10
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of C4 Therapeutics is ―. C4 Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio4.40
PB Ratio0.62
Price to Fair Value0.62
Price to FCF-1.59
Price to Operating Cash Flow-4.73
PEG Ratio0.09
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 35.95M and earned -104.99M in profits. Earnings per share was -1.27.
Revenue35.95M
Gross Profit27.97M
Operating Income-104.49M
Pretax Income-104.87M
Net Income-104.99M
EBITDA-102.91M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -95.35M and capital expenditures -671.00K, giving a free cash flow of -96.02M billion.
Operating Cash Flow-95.35M
Free Cash Flow-96.02M
Free Cash Flow per Share-0.87
Dividends & Yields
C4 Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.39
52-Week Price Change57.71%
50-Day Moving Average3.85
200-Day Moving Average2.80
Relative Strength Index (RSI)40.06
Average Volume (3m)3.51M
Important Dates
C4 Therapeutics upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
C4 Therapeutics as a current ratio of 7.81, with Debt / Equity ratio of 24.95%
Current Ratio7.81
Quick Ratio7.81
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, C4 Therapeutics has paid 121.00K in taxes.
Income Tax121.00K
Effective Tax Rate>-0.01
Enterprise Valuation
C4 Therapeutics EV to EBITDA ratio is -1.40, with an EV/FCF ratio of -1.45.
EV to Sales4.00
EV to EBITDA-1.40
EV to Free Cash Flow-1.45
EV to Operating Cash Flow-1.46
Balance Sheet
C4 Therapeutics has $235.67M in cash and marketable securities with $58.45M in debt, giving a net cash position of $177.22M billion.
Cash & Marketable Securities$235.67M
Total Debt$58.45M
Net Cash$177.22M
Net Cash Per Share$1.60
Tangible Book Value Per Share$3.10
Margins
Gross margin is 94.83%, with operating margin of -290.68%, and net profit margin of -292.08%.
Gross Margin94.83%
Operating Margin-290.68%
Pretax Margin-291.74%
Net Profit Margin-292.08%
EBITDA Margin-286.29%
EBIT Margin-291.74%
Analyst Forecast
The average price target for C4 Therapeutics is $10.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.33
Price Target Upside253.88% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-12.37%
EPS Growth Forecast19.59%